<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173262</url>
  </required_header>
  <id_info>
    <org_study_id>20140380-01H</org_study_id>
    <nct_id>NCT02173262</nct_id>
  </id_info>
  <brief_title>REaCT Integrated Consent Model to Compare Two Standard of Care Regimens</brief_title>
  <acronym>OTT14-03</acronym>
  <official_title>Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Integrated Consent Model is being increasingly used internationally to improve patient
      care. In this feasibility study we will explore whether the model is feasible in practice;
      and whether it can be used to increase the number of physicians and patients who take part in
      clinical trials, and address the critical issue around the optimal febrile neutropenia
      prevention by randomizing eligible patients to either G-CSF or ciprofloxacin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of randomized patients in each physician's practice</measure>
    <time_frame>every 4 weeks up to 2 years</time_frame>
    <description>The percentage of randomized patients will be measured by collecting reasons for NOT complying with, or &quot;opting-out&quot; of the randomized selection compared to the overall accrual.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rates of febrile neutropenia</measure>
    <time_frame>Once when the last participant completes chemotherapy up to year 2</time_frame>
    <description>Rates of febrile neutropenia will be compared between Ciprofloxacin and G-CSF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>granulocyte-colony stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <other_name>Cipro</other_name>
    <other_name>Cipro XR</other_name>
    <other_name>Proquin XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary breast cancer

          -  Planned TC chemotherapy

          -  ≥19 years of age

          -  Able to provide verbal consent

          -  Willing to complete a survey

        Exclusion Criteria:

        • Contraindication to either Ciprofloxacin or G-CSF
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Clemons, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

